8-K: Bio-Techne Reports Strong Q2 Fiscal 2025 Results and Appoints New Board Member

Bio-Techne announces positive Q2 FY2025 results with 9% organic revenue growth and the appointment of Dr. Amy Herr to its Board of Directors.

Summary

• Bio-Techne Corporation reported its financial results for the second quarter of fiscal year 2025, ending December 31, 2024.
• The company's organic revenue increased by 9% to $297.0 million.
• GAAP earnings per share (EPS) was $0.22, compared to $0.17 in the same quarter last year.
• Adjusted EPS was $0.42, up from $0.40 in the prior year.
• The Protein Sciences segment saw a 7% increase in net sales to $211.6 million, with 8% organic revenue growth.
• The Diagnostics and Spatial Biology segment's net sales increased by 12% to $84.1 million, with 12% organic revenue growth.
• Bio-Techne's Board of Directors declared a dividend of $0.08 per share, payable on February 28, 2025, to shareholders of record on February 17, 2025.
• Dr. Amy Herr was appointed to the Board of Directors as an independent director, effective February 1, 2025.
• Dr. Herr will serve on the Science & Technology Committee of the Board of Directors.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and a strategic board appointment. The company is performing well in its key segments, and management expresses confidence in future growth.

Positives

• Strong organic revenue growth of 9% indicates healthy business performance.
• Increased GAAP and adjusted EPS reflect improved profitability.
• Growth in both the Protein Sciences and Diagnostics & Spatial Biology segments demonstrates diversified strength.
• The declaration of a dividend signals confidence in the company's financial stability.
• The appointment of Dr. Amy Herr to the Board of Directors brings valuable expertise in bioengineering and life sciences.

Negatives

• The Diagnostics and Spatial Biology segment's operating margin decreased to 3.9% from 6.0% due to re-instatement of incentive compensation accruals, partially offset by favorable volume leverage.
• Adjusted operating margin remained flat at 30.1% due to favorable volume leverage offset by re-instatement of incentive compensation accruals.

Risks

• The press release mentions forward-looking statements that involve risks and uncertainties, including the effect of new branding and marketing initiatives, integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

Future Outlook

The company's future performance is subject to various factors, including the integration of new businesses, the introduction and acceptance of new products, and general economic conditions.

Management Comments

• Kim Kelderman, President and Chief Executive Officer of Bio-Techne, stated that the company delivered strong second quarter results and is seeing early signs of improvement in the biopharma end-market.
• Kelderman added that the company's growth vectors empower the discovery of novel biological insights, the development and manufacturing of advanced therapeutics and, enable precision diagnostics.
• Bob Baumgartner, Chairman of the Board of Bio-Techne, stated that Dr. Herr brings tremendous scientific experience to Bio-Techne.

Industry Context

Bio-Techne operates in the life sciences industry, providing tools and reagents for research and clinical diagnostics. The company's performance is influenced by trends in biopharma, cell and gene therapy, and spatial biology.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without knowing Bio-Techne's specific competitors and their recent results.
• However, companies like Danaher, Thermo Fisher Scientific, and Agilent Technologies are major players in the life sciences space.
• Comparing Bio-Techne's organic revenue growth and operating margins to these companies' results would provide a better understanding of its relative performance.
• For example, if Danaher and Thermo Fisher are reporting similar organic growth rates, it would suggest Bio-Techne is performing in line with industry trends.
• If Bio-Techne's operating margins are significantly higher or lower, it could indicate differences in efficiency or pricing strategy.

Management Changes

Related Party Transactions

• Dr. Herr's partner, Josh Molho, is a Senior Director of Project Management at a subsidiary of the Company and is expected to earn total compensation in excess of $120,000 for the current fiscal year.

Stakeholder Impact

• Shareholders will benefit from the declared dividend and the company's strong financial performance.
• Employees may experience increased opportunities due to the company's growth.
• Customers will continue to have access to innovative tools and reagents.
• The appointment of Dr. Herr could lead to new strategic directions and innovations.

Next Steps

• The company will host an earnings conference call on February 5, 2025.
• The Board of Directors will consider future cash dividends on a quarterly basis.

Key Dates

Keywords

Bio-Techne, Financial Results, Board Appointment, Amy Herr, Dividend, Protein Sciences, Diagnostics, Spatial Biology, Organic Revenue, EPS